Fentanyl has been incorporated into a transdermal therapeutic system (TTS) containing a
rate-limiting membrane that provides constant release of the opioid. TTS fentanyl provides …

A multicenter study was conducted to determine the patient and physician acceptability of
transdermal fentanyl in the management of cancer-related pain. In this study, 10 cancer …

The transdermal therapeutic system (TTS) for fentanyl is a drug‐delivery system for use in
patients with chronic pain who require an opioid analgesic. A multicentre, randomized …

Alternative routes of drug delivery have particular relevance for use in chronic pain. When
the pain experience is constant or nearly constant, a continuous infusion of drug is an ideal …

The long-term therapy of 51 patients using transdermal fentanyl was evaluated. The
transdermal therapy was performed for 158 days (range, 15–855 days). The need for …

Transdermal fentanyl is a new fentanyl delivery system recently approved by the FDA for use
in patients with chronic pain. In an open-label clinical trial, 5 patients with cancer pain were …

Many cancer patients are undermedicated and inappropriately managed for pain, leading to
a diminished quality of life. Patients with moderate to severe pain often require opioid …

A prospective phase II study was conducted to define the analgesic efficacy, acceptability
and toxicity of the transdermal therapeutic system (TTS) of fentanyl in Chinese patients with …

In this study, 6 patients with pain from advanced cancer were enrolled in a multicenter, open-
label seeding trial of transdermal fentanyl. Following equianalgesic dose conversion …

Transdermal (TTS) fentanyl therapy has emerged as an effective alternative to the use of
oral opioids for the control of pain in certain cancer patients. These patients are those with …